Last reviewed · How we verify
Twinrix™ Junior
Twinrix Junior is a combined vaccine that stimulates the immune system to produce antibodies against hepatitis A and hepatitis B viruses.
Twinrix Junior is a combined vaccine that stimulates the immune system to produce antibodies against hepatitis A and hepatitis B viruses. Used for Prevention of hepatitis A and hepatitis B in infants and children (typically ages 12 months to 18 years).
At a glance
| Generic name | Twinrix™ Junior |
|---|---|
| Also known as | Combined hepatitis A and B vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated viral vaccine (combination) |
| Target | Hepatitis A virus and Hepatitis B surface antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated hepatitis A virus and recombinant hepatitis B surface antigen, which trigger both humoral and cellular immune responses. This results in the production of protective antibodies (anti-HAV and anti-HBs) that prevent infection by these two hepatitis viruses. The junior formulation contains lower antigen doses than the adult version, appropriate for pediatric immunization.
Approved indications
- Prevention of hepatitis A and hepatitis B in infants and children (typically ages 12 months to 18 years)
Common side effects
- Injection site pain/soreness
- Fever
- Fatigue
- Headache
- Myalgia
Key clinical trials
- Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™ (PHASE4)
- Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared (PHASE3)
- Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 (PHASE3)
- Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Twinrix™ Junior CI brief — competitive landscape report
- Twinrix™ Junior updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI